person · Reporting owner
Lillie James Woodruff
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MapLight Therapeutics, Inc.MPLT · Entity 5316 | Chief Scientific Officer | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MapLight Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 210,110 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 7,730 · Balance 210,110 F1: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.25 · Expires 2036-08-16 | Direct | 31,395 |
Reported balance
After 2026-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-17 · Grant · Acquired 31,395 · Balance 31,395 F3: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
F2: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tempest Therapeutics, Inc.
Report date December 07, 2018 · Filed December 12, 2018
Section 16 reporting ended · disclosed 2018-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2028-05-10 | Direct | 8,333 |
Reported balance
After 2018-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-10 · Grant · Acquired 8,333 · Balance 8,333 F1: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F2: The Reporting Person has the right to exercise these options for a three-year period after any termination of his employment (other than for cause). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.
F2: The Reporting Person has the right to exercise these options for a three-year period after any termination of his employment (other than for cause).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 22:35 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 31,395 | $0.00 Strike: $11.25 | $0.00 |
DisclosureSEC source: 0001728746-26-000016 · form4-08192026_060808.xml · derivative · entry 2 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,395 Underlying: Voting Common Stock · 31,395 shares Expires 2036-08-16 F3 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 22:35 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 7,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001728746-26-000016 · form4-08192026_060808.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,110 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 00:39 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 22,082 | $12.54 | $276,908.28 |
DisclosureSEC source: 0001728746-26-000014 · form4-08052026_120851.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,380 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.12 to $12.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 17, 2026 Filed Jul 18, 2026 01:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 2,077 | $37.90 | $78,718.30 |
DisclosureSEC source: 0001728746-26-000012 · form4-07182026_010728.xml · nonDerivative · entry 7 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,462 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 12 | $37.96 | $455.52 |
DisclosureSEC source: 0001728746-26-000012 · form4-07182026_010728.xml · nonDerivative · entry 6 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,539 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 3,526 | $37.26 | $131,378.76 |
DisclosureSEC source: 0001728746-26-000012 · form4-07182026_010728.xml · nonDerivative · entry 5 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,551 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 5,009 | $36.45 | $182,578.05 |
DisclosureSEC source: 0001728746-26-000012 · form4-07182026_010728.xml · nonDerivative · entry 4 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,077 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 12 | $37.54 | $450.48 |
DisclosureSEC source: 0001728746-26-000012 · form4-07182026_010728.xml · nonDerivative · entry 3 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,086 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 5,393 | $36.99 | $199,487.07 |
DisclosureSEC source: 0001728746-26-000012 · form4-07182026_010728.xml · nonDerivative · entry 2 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,098 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 2,238 | $36.00 | $80,568.00 |
DisclosureSEC source: 0001728746-26-000012 · form4-07182026_010728.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,491 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5251 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 721 | $28.28 | $20,389.88 |
DisclosureSEC source: 0001728746-26-000010 · form4-05112026_090501.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,729 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.08 to $28.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 16,421 | $29.13 | $478,343.73 |
DisclosureSEC source: 0001728746-26-000008 · form4-05062026_080505.xml · nonDerivative · entry 8 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,450 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 8,390 | $28.04 | $235,255.60 |
DisclosureSEC source: 0001728746-26-000008 · form4-05062026_080505.xml · nonDerivative · entry 7 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,871 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 963 | $29.00 | $27,927.00 |
DisclosureSEC source: 0001728746-26-000008 · form4-05062026_080505.xml · nonDerivative · entry 6 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,261 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 10,132 | $28.12 | $284,911.84 |
DisclosureSEC source: 0001728746-26-000008 · form4-05062026_080505.xml · nonDerivative · entry 5 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,224 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 705 | $30.08 | $21,206.40 |
DisclosureSEC source: 0001728746-26-000008 · form4-05062026_080505.xml · nonDerivative · entry 4 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 279,356 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 320 | $29.56 | $9,459.20 |
DisclosureSEC source: 0001728746-26-000008 · form4-05062026_080505.xml · nonDerivative · entry 3 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,061 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 5,526 | $28.37 | $156,772.62 |
DisclosureSEC source: 0001728746-26-000008 · form4-05062026_080505.xml · nonDerivative · entry 2 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,381 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 9,250 | $27.50 | $254,375.00 |
DisclosureSEC source: 0001728746-26-000008 · form4-05062026_080505.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,907 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 2,097 | $27.49 | $57,646.53 |
DisclosureSEC source: 0001728746-26-000006 · form4-04172026_040408.xml · nonDerivative · entry 3 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,157 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 686 | $27.01 | $18,528.86 |
DisclosureSEC source: 0001728746-26-000006 · form4-04172026_040408.xml · nonDerivative · entry 2 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,254 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 1,730 | $26.82 | $46,398.60 |
DisclosureSEC source: 0001728746-26-000006 · form4-04172026_040408.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,940 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5). F3 · balance_after: Includes 808 shares acquired under the Issuer's stock purchase plan on March 31, 2026. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 31,395 | $0.00 Strike: $15.70 | $0.00 |
DisclosureSEC source: 0001728746-26-000004 · form4-02092026_050209.xml · derivative · entry 2 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,395 Underlying: Voting Common Stock · 31,395 shares Expires 2036-02-04 F3 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 7,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001728746-26-000004 · form4-02092026_050209.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,862 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | Tax withholdingVoting Common Stock | 45,055 | $17.98 | $810,088.90 |
DisclosureSEC source: 0001728746-26-000002 · form4-01292026_040111.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,132 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 132,023 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001728746-25-000007 · form4-10282025_041010.xml · derivative · entry 2 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,023 Underlying: Voting Common Stock · 132,023 shares Expires 2035-10-26 F3 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 32,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001728746-25-000007 · form4-10282025_041010.xml · nonDerivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,539 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| May 10, 2018 Filed Dec 12, 2018 00:46 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-18-062124 · doc4.xml · derivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2028-05-10 F1 · derivative.exercise_price: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F1 · shares: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F2 · derivative.exercise_date: The Reporting Person has the right to exercise these options for a three-year period after any termination of his employment (other than for cause). F1 · derivative.underlying_shares: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F1 · balance_after: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 22:56 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantStock Option (right to buy) · Derivative | 357,057 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001179110-18-003673 · edgar.xml · derivative · entry 1 Lillie James Woodruff · CIK 0001728746 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,057 Underlying: Common Stock · 357,057 shares Expires 2028-03-05 F1 · derivative.exercise_date: The shares underlying this option shall vest as to 25% of the shares on the first anniversary of the commencement of the Reporting Person's employment (which began on January 16, 2018), with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.